Gas gangrene
diseaseOn this page
Also known as myonecrosis
Summary
Gas gangrene (MONDO:0005767) is a disease and 5 clinical trials. Top therapeutic interventions include sodium chloride. A subtype of commensal bacterial infectious disease — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Clinical trials: 5
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | gas gangrene |
| Mondo ID | MONDO:0005767 |
| EFO | EFO:0007279 |
| MeSH | D005738 |
| DOID | DOID:9159 |
| ICD-10-CM | A48.0 |
| ICD-11 | 1920227791 |
| SNOMED CT | 80466000 |
| UMLS | C0017105 |
| MedGen | 8959 |
| GARD | 0024229 |
| Is cancer (heuristic) | no |
Also known as: gas gangrene · myonecrosis
Disease family
This is a subtype of commensal bacterial infectious disease. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by etiologic mechanism › disease of primarily extrinsic mechanism › infectious disease › bacterial infectious disease › commensal bacterial infectious disease › gas gangrene
Related subtypes (5): toxic shock syndrome, actinomycosis, chlamydia trachomatis infectious disease, Lemierre syndrome, staphylococcal scalded skin syndrome
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 5.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| Not specified | 3 |
| PHASE4 | 1 |
| PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01430377 | PHASE4 | UNKNOWN | Side Branch Predilatation Strategy in Coronary Bifurcation Lesion Stenting (SBPS) |
| NCT02111161 | PHASE2 | COMPLETED | Immunoglobulin for Necrotizing Soft Tissue Infections: a Randomised Controlled Trial |
| NCT02180906 | Not specified | COMPLETED | Biomarkers in Patients With Flesh-eating Bacterial Infections |
| NCT02501382 | Not specified | COMPLETED | Modulation of Biomarkers in Patients With Flesh-eating Bacterial Infections After With Hyperbaric Oxygen Treatment |
| NCT03147352 | Not specified | COMPLETED | Prognosis and Treatment of Necrotizing Soft Tissue Infections: A Prospective Cohort Study |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| SODIUM CHLORIDE | 4 | 1 |
Related Atlas pages
- Drugs: Sodium Chloride